Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Jelle A. Spoorendonk
12  Ergebnisse:
Personensuche X
?
1

A cost-consequence model of using the 21-gene assay to iden..:

Simons, Martijn J. H. G. ; Machielsen, Peter M. ; Spoorendonk, Jelle A....
Journal of Medical Economics.  27 (2024)  1 - p. 445-454 , 2024
Link: https://doi.org/10.1080/..
 
?
2

Cost and Clinical Benefits Associated with Oncotype DX® Tes..:

de Jongh, Felix E. ; Efe, Reva ; Herrmann, Kirsten H...
International Journal of Breast Cancer.  2022 (2022)  - p. 1-12 , 2022
Link: https://doi.org/10.1155/..
 
?
3

Clinical evidence of interventions assessed in Friedreich a..:

Jain, Paridhi ; Badgujar, Lohit ; Spoorendonk, Jelle.
Therapeutic Advances in Rare Disease.  3 (2022)  - p. 263300402211398 , 2022
Link: https://doi.org/10.1177/..
 
?
4

2-Year Real-World Outcomes with Intravitreal Aflibercept in..:

Carrasco, Joao ; Daien, Vincent ; Eldem, Bora M...
Ophthalmology and Therapy.  10 (2021)  3 - p. 397-411 , 2021
Link: https://doi.org/10.1007/..
 
?
5

A cost-consequence model of using the 21-gene assay to iden..:

Martijn J.H.G. Simons ; Peter M. Machielsen ; Jelle A. Spoorendonk...
doi:10.6084/m9.figshare.25334767.v1.  , 2024
Link: https://doi.org/10.6084/..
 
?
6

A cost-consequence model of using the 21-gene assay to iden..:

Martijn J.H.G. Simons ; Peter M. Machielsen ; Jelle A. Spoorendonk...
doi:10.6084/m9.figshare.25334767.v1.  , 2024
Link: https://doi.org/10.6084/..
 
?
7

Clinical evidence of interventions assessed in Friedreich a..:

Jain, Paridhi ; Badgujar, Lohit ; Spoorendonk, Jelle.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032438/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
8

Cost and Clinical Benefits Associated with Oncotype DX® Tes..:

Felix E. de Jongh ; Reva Efe ; Kirsten H. Herrmann.
http://dx.doi.org/10.1155/2022/5909724.  , 2022
Link: https://doi.org/10.1155/..
 
?
9

2-Year Real-World Outcomes with Intravitreal Aflibercept in..:

Carrasco, Joao ; Daien, Vincent ; Eldem, Bora..
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40123-021-00350-5.  , 2021
Link: https://hal.umontpellier..
 
?
10

2-Year Real-World Outcomes with Intravitreal Aflibercept in..:

Daien, Vincent ; Carrasco, Joao ; Yoon, Jisu..
ead29dc2-1f9f-4941-8806-d55b572ff073.  , 2021
Link: https://doi.org/10.1007/..
 
?
11

2-Year Real-World Outcomes with Intravitreal Aflibercept in..:

Carrasco, Joao ; Daien, Vincent ; Eldem, Bora M..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319257/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
12

2-Year Real-World Outcomes with Intravitreal Aflibercept in..:

Adis Rapid Journals on behalf of: (10331616) ; Joao Carrasco (7509890) ; Vincent Daien (438379)...
https://figshare.com/articles/media/2-Year_Real-World_Outcomes_with_Intravitreal_Aflibercept_in_Neovascular_Age-Related_Macular_Degeneration_Literature_Review_and_Meta-Analysis_of_Patient-Relevant_Outcomes/14510706.  , 2021
Link: https://doi.org/10.6084/..
 
1-12